ARLINGTON, VIRGINIA / ACCESS Newswire / January 22, 2025 / The Centers for Medicare & Medicaid Services (CMS) has announced an additional 15 drugs that will be subject to price controls under the Inflation Reduction Act (IRA).

The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by introducing floors.

In November, a federal judge ordered CMS to recalculate UnitedHealthcare's Medicare Advantage Star Ratings for the 2025 plan year.

Transparency in the program is more than just a mechanism for fair pricing—it is a driving force that diminishes the returns on non-innovative expenditures such as lobbying, so that resources could be reallocated to high-value,

Final rule makes it easier for CMS to suspend agents and brokers who exchange plans without notifying the Medicare customer.

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated prices for Ozempic, Wegovy, and Rybelsus will be. In Medicare's negotiations for 2026, the new prices achieved an average of 22% savings.

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. The CMS listed Ozempic, Rybelsus and Wegovy — all forms of

The Centers for Medicare and Medicaid Services will issue corrected data on Medicare Advantage enrollment the week of Jan. 20.

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

Federal health agencies, including the Centers for Medicare & Medicaid Services, have halted their communication efforts in the first days of the Trump administration.

The General Enrollment Period provides an opportunity to make up for a past oversight – the failure to enroll in Part B.